Stockscreener 앱 받기
12.49
1.54%
0.185
전일 마감가:
$12.31
열려 있는:
$12.02
하루 거래량:
3.72M
Relative Volume:
0.52
시가총액:
$4.05B
수익:
$79.21M
순이익/손실:
$-143.96M
주가수익비율:
-26.05
EPS:
-0.4796
순현금흐름:
$-189.60M
1주 성능:
-1.81%
1개월 성능:
+17.81%
6개월 성능:
+277.64%
1년 성능:
+162.05%
1일 변동 폭
$11.78
$12.67
1주일 범위
$11.78
$12.97
52주 변동 폭
$2.745
$13.18
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
12.49 | 3.99B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
522.55 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.25 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.15 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.08 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
197.92 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
ABCL Reinstated by Goldman Sachs -- Neutral Rating with Price Ta - GuruFocus
Goldman Sachs resumes AbCellera stock coverage with neutral rating By Investing.com - Investing.com Canada
ABCL Looks 201.0% Overvalued on GF Value™ - GuruFocus
AbCellera Biologics Inc. (ABCL) Options Chain - Yahoo Finance
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know - Yahoo Finance
ABCL Should I Buy - Intellectia AI
AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech Gem With A 34% Upside Potential - DirectorsTalk Interviews
Biotech Stocks At 52-Week HighsMNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO - RTTNews
Abcellera Biologics stock hits 52-week high at 12.58 USD By Investing.com - Investing.com Australia
Abcellera Biologics stock hits 52-week high at 12.58 USD - Investing.com
Abcellera Biologics Inc (ABCL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AbCellera to present phase 2 data on menopause treatment drug By Investing.com - Investing.com Nigeria
ABCL Looks 171.0% Overvalued on GF Value™ - GuruFocus
AbCellera to present phase 2 data on menopause treatment drug - Investing.com
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 - Business Wire
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes By Investing.com - Investing.com South Africa
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes - Investing.com
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - Investing News Network
symbol__ Stock Quote Price and Forecast - CNN
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
AbCellera Biologics (ABCL) Q4 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying - Quiver Quantitative
Historical Data for AbCellera Biologics Inc. Tokenized Stock (Robinhood) in USD - CryptoRank
What'sGoing On With AbCellera Biologics Stock On Tuesday? - Benzinga
ABCL Stock Surges As ABCL635 Data Reprices Hot-Flash Market - timothysykes.com
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Punaises (dD09m2oJ3D) - Mshale
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain? - simplywall.st
Abcellera director John S. Montalbano acquires common shares worth $110,300 - Bitget
AbCellera Biologics Director John S. Montalbano Acquires 10,000 Shares on August 18, 2026 - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Montalbano John S. - Moomoo
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15 - Moomoo
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - AOL.com
Abcellera Biologics stock hits 52-week high at 11.51 USD - Investing.com
Abcellera Biologics stock hits 52-week high at 11.51 USD By Investing.com - Investing.com India
Why AbCellera (ABCL) Is Up 64.2% After Menopause Trial Win, Equity Raise And Vertex Deal - simplywall.st
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity - Yahoo Finance
AbCellera Biologics Stock (ABCL) Opinions on Positive Phase 2 Trial Results - Quiver Quantitative
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Yahoo Finance
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price, MarketCap, Charts and Fundamentals Info - BeInCrypto
AbCellera CFO Andrew Booth Acquires 37,200 Shares at $10.32 Each - Kalkine Media
AbCellera Biologics Director Michael R. Hayden Acquires 46,387 Shares at $10.37 Average Price - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Booth Andrew - Moomoo
AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85% - Trefis
6 Green Days In A Row: AbCellera Biologics Stock Is Up 85% - Trefis
AbCellera Biologics (ABCL) Slips 2.32% to $10.71 as Biotech Sentiment CoolsMcClellan Summation - careplusvn.com
AbCellera prices US $200M offering at US $9.75 a share - Private Capital Journal
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Hayden Michael R - Moomoo
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.25%
1.51%
자본화:
|
볼륨(24시간):